All In Biotech

Drug Trial Radar · NCT05145010

Extension Study of Infigratinib in Children With Achondroplasia (ACH)

Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children With Achondroplasia: PROPEL OLE

Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

325

Planned (sponsor's estimate)

Start

Dec 6, 2021

Primary completion

Dec 1, 2031

Study completion Feb 1, 2032

Sponsor

Sponsor type
Industry
First posted
Dec 6, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 3 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, multicenter, open-label, extension (OLE) study to evaluate the long-term safety, tolerability, and efficacy of infigratinib, an FGFR 1-3-selective tyrosine kinase inhibitor, in participants with ACH who previously completed a QED-sponsored interventional study, and in additional participants who are naïve to infigratinib treatment. Quality of Life assessments for this participant population will also be evaluated. Treatment-naïve participants must have at least a 6-month period of growth assessment in study QBGJ398-001 (PROPEL) and will be enrolled in this OLE study if the sponsor deems additional long-term safety and/or efficacy data are necessary, and participants are not otherwise eligible to enroll in another QED-sponsored Phase 2 or Phase 3 ACH study.

Conditions

  • Achondroplasia

Interventions

  • InfigratinibDrug

    Infigratinib minitablets or sprinkle capsules to be administered by mouth. In participants that completed a prior study with infigratinib, the starting dose will be the same as the last dose received in the prior interventional study with infigratinib. Infigratinib dose may be adjusted to 0.25 mg/kg/day.

  • InfigratinibDrug

    Infigratinib sprinkle capsules to be administered by mouth. Starting dose for the participants naïve to Infigratinib will be 0.25 mg/kg/day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment emergent adverse events (TEAE) and serious TEAETime frame: 10 years
  2. Changes over time in height Z-score in relation to ACH and general pediatric population tablesTime frame: 10 years

Locations

31 sites in 10 countries. Site status is shown where the registry gives one.

  • UCSF Benioff Children's Hospital, Oakland

    Oakland, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • Nemours Alfred I. Dupont Hospital for Children

    Wilmington, Delaware

  • Johns Hopkins University

    Baltimore, Maryland

  • University of Missouri

    Columbia, Missouri

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • University Hospital and UW Health Clinics

    Madison, Wisconsin

  • Hospital de Pediatría SAMIC Prof. Dr. Juan P. Garrahan

    Ciudad Autonoma Buenos Aires, Buenos Aires, Argentina

  • Murdoch Children's Hospital

    Parkville, Victoria, Australia

  • Stollery Children's Hospital

    Edmonton, Alberta, Canada

  • Children's Hospital - London Health Sciences Centre

    London, Ontario, Canada

  • Children's Hospital of Eastern Ontario

    Ottawa, Ontario, Canada

  • Centre Hospitalier Universitaire Sainte-Justine

    Montreal, Quebec, Canada

  • Hopital Femme Mere Enfant

    Lyon, France

  • Hopital Necker-Enfants Malades

    Paris, France

  • Hopital des Enfants

    Toulouse, France

  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

    Milan, Italy

  • Policlinico A. Gemelli IRCCS

    Roma, Italy

  • Haukeland University Hospital

    Bergen, Norway

  • Oslo University Hospital

    Oslo, Norway

  • KK Women's and Children's Hospital

    Singapore, Singapore

  • Hospital Universitario La Paz

    Madrid, Spain

  • Hospital Universitario Virgen de la Victoria

    Málaga, Spain

  • Hospital Vithas San José

    Vitoria-Gasteiz, Álava, Spain

  • Birmingham Women's and Children's NHS Foundation Trust

    Birmingham, United Kingdom

  • University Hospitals Bristol and Weston NHS Foundation Trust

    Bristol, United Kingdom

  • Queen Elizabeth University Hospital

    Glasgow, United Kingdom

  • St. Thomas' Hospital

    London, United Kingdom

  • Manchester University Children's Hospital

    Manchester, United Kingdom

  • Sheffield Children's Hospital

    Sheffield, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.